24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Pharma
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
14:05
“Rather than head-count cuts, we reallocate,” says VP HR at Coralogix
12:17
“I don’t think there’s such a thing as over-reliance on AI”
11:46
Google’s $2.7B AI deal with Noam Shazeer's Character.AI draws DOJ attention
10:47
Full list of Israeli startup M&As in 2025
More stories
Buzz
Most popular
Daily
Weekly
1
Wix acquires Hour One, accelerating its push into AI-powered digital experiences
2
Fortinet acquires Israeli cyber startup Suridata for tens of millions to boost SaaS protection
3
Gigi Levy-Weiss and Redis co-founder Yiftach Shoolman launch defense tech startup Line 5, raising $20M Seed round
4
The 50 most promising Israeli startups - 2025
5
Michael Levitt Analysis: Corona Is Slowing Down, Humanity Will Survive
More news
Pharma
12 stories about Pharma
Teva Announces Restructuring, Ousts Second in Command
27.11.17
|
Golan Hazani
The troubled Israeli drugmaker has combined its generic and specialty drug divisions, effective immediately
Generic Focus made Kite Pharma Founder Leave Teva
13.11.17
|
Dror Reich
Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"
With New CEO in Seat, Teva Lowers Outlook
02.11.17
|
Lilach Baumer and Dror Reich
Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone
Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market
31.10.17
|
Lilach Baumer
Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot
Teva Loses Copaxone Market Exclusivity
04.10.17
|
Lilach Baumer
Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug
New CEO to Break Teva’s Copaxone Habit
11.09.17
|
Sophie Shulman, Dror Reich
Troubled drugmaker says new CEO must work to quickly regain its financial credibility
Teva Appoints Lundbeck's Schultz as CEO
11.09.17
|
Dror Reich and Micky Grunfeld
The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated
Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO
31.08.17
|
Dror Reich
The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology
Anti-Acne Drug Developer Plans Nasdaq IPO
15.08.17
|
Golan Hazani
Sol-Gel approached potential underwriters. It aims to go public before the end of the year
Allergan Sketches Road Show to Sell Teva Stake
14.08.17
|
Golan Hazani
The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter
With Bloated Debt, Teva Looks to Sell Assets
10.08.17
|
Eli Shimony and Gil Kalian
The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016
Teva’s Perfect Storm Sends Tel-Aviv Stock Exchange Down
06.08.17
|
Calcalist
Teva’s stock price dropped sharply on Thursday and Friday after the company released quarterly revenue and profits that fell short of analysts’ forecasts
Previous Articles